Milestone Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIST research report →
Range $3 – $3
Price Chart
About the company
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development.
- CEO
- Joseph G. Oliveto
- IPO
- 2019
- Employees
- 38
- HQ
- Montreal, QC, CA
Get TickerSpark's AI analysis on MIST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46.20M
- P/E
- -0.50
- Fwd P/E
- 2.61
- PEG
- -0.07
- P/S
- 8.80
- P/B
- -8.50
- EV/EBITDA
- 0.43
- Div Yield
- 0.00%
- Gross Margin
- 91.95%
- Op Margin
- -1728.44%
- Net Margin
- -1844.80%
- ROE
- -435.92%
- ROIC
- -66.58%
Latest fiscal year · YoY change
- Revenue
- $1.55M+0.0%
- Gross Profit
- $1.43M+0.0%
- Op Income
- $-62,485,000
- Net Income
- $-63,058,000-51.9%
- EPS
- $-0.75-11.9%
- OCF Growth
- -70.0%
- FCF Growth
- -70.8%
- 52W High
- $3.06
- 52W Low
- $0.36
- 50D MA
- $0.75
- 200D MA
- $1.28
- Beta
- 1.07
- RSI (14)
- 30
- Avg Volume
- 1.54M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Milestone reported steady early CARDAMYST launch growth, expanded commercial coverage, and announced major cost cuts to extend runway into late 2028.· November 13, 2026
- Q3 CARDAMYST prescriptions rose to approximately 1,800, up 50% from Q2, with about 750 unique prescribers and total scripts since launch of about 3,400.
- Commercial formulary coverage expanded to roughly two-thirds of commercially covered lives, up from about 50% last quarter and about 25% at the end of Q2.
- Management announced restructuring actions that they expect to reduce operating expenses by about 30% and extend cash runway into late 2028.
- The company said ReVeRA-301 is now enrolling in the U.S., Canada, and Europe, and reiterated a phase III readout in the second half of 2028.
- Management said early launch demand is improving, but growth is still being shaped by payer access, physician adoption, and targeted commercial execution.
Net product revenue was $1.0 million in Q3 2026 versus $0.6 million in Q2 2026; nine-month revenue was $1.8 million, with no product revenue in the comparable 2025 periods. Q3 R&D expense, net of tax credits, was $3.5 million versus $3.9 million a year ago; SG&A was $24.2 million versus $7.9 million a year ago. Q3 net loss was $25.8 million, or $0.18 per share, versus a net loss of $11.9 million, or $0.12 per share, last year. The company ended the quarter with $145.4 million in cash equivalents and short-term investments, up from $106 million at December 31, 2025. Management expects the restructuring to lower operating expenses by approximately 30%, with about $2 million in one-time charges, and said the amended RTW note agreement extends the PIK interest period from March 31, 2027 to March 2029; runway is now expected into late 2028 and through the anticipated ReVeRA-301 phase III readout in 2H 2028.
Joseph Oliveto emphasized that the launch is still early but is trending better, with August and September reflecting the impact of optimizing the sales force to 45 reps and sharpening targeting. He framed the restructuring as a deliberate shift from launch mode to a more efficient growth model, while preserving resources for ReVeRA-301 and the longer-term PSVT opportunity. His tone was constructive and pragmatic: he said the company is pleased with steady growth, but wants a more focused organization to support adoption and conserve cash.
Anthony Krick reported the quarter’s financials and cash position, highlighting $1.0 million of net product revenue, $3.5 million of net R&D expense, $24.2 million of SG&A, and a $25.8 million net loss, or $0.18 per share. He also noted nine-month net product revenue of $1.8 million, R&D of $10.2 million, SG&A of $67.5 million, and a nine-month net loss of $80.5 million, or $0.59 per share. He ended by saying the company had $145.4 million in cash equivalents and short-term investments at quarter-end.
Analysts focused on how growth should progress in Q4 and Q1 under the new 45-rep model, and management said it expects continued script inflection in Q4 but possible seasonal flattening in Q1 as patient out-of-pocket costs and plan resets affect retail drugs. Questions also centered on ReVeRA-301 design, with management reiterating a target of about 150 events over roughly two years, an expected enrollment range of 500 to 700 patients, and a second-half 2028 data readout. Analysts asked about field targeting, emergency-department and EMT usage, and patient support/fill rates; management said the current priority is outpatient cardiology and electrophysiology, while emergency and EMT channels are viewed as real but longer-term opportunities because of operational complexity. On access and abandonment, management said fill rates are improving and are benchmarking well versus comparable products, and that access is not the primary obstacle to growth.
Management said CARDAMYST prescription growth is accelerating from a small base, prescriber breadth is expanding, and about 40% of prescribers have written more than one patient, suggesting depth may improve over time. Commercial coverage has widened to about two-thirds of commercially covered lives, and management expects further payer gains, including potential future CVS Caremark coverage. The cost cuts, in-house sales transition, and RTW amendment meaningfully extend runway, giving the company more time to build the PSVT franchise and advance AFib-RVR.
Management acknowledged that growth is still constrained by physician action, patient access workflows, and the time it takes for a new retail drug to become embedded in routine practice. They also said Q1 could soften seasonally, Medicare will likely not be a major growth driver near term, and they will not chase broad Part D coverage at any rebate level. The restructuring includes headcount reductions and leadership departures, and the company still has to prove that the current launch trajectory can sustain itself beyond early adopters and into broader cardiology use.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.1%
- Shares Outstanding
- 124.50M
- Float Shares
- 122.10M
of shares held by institutions
86 13F filers
Buy/sell ratio 7.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Propel Bio Management, LLC | 9.45M | ▲ 2.02M |
| Pavaki Capital Management LLC | 9.34M | ▲ 270.00K |
| Rtw Investments, LP | 7.83M | 0 |
| Point72 Asset Management, L.P. | 5.47M | ▲ 56.11K |
| Simplify Asset Management Inc. | 3.35M | 0 |
| Millennium Management LLC | 2.24M | ▼ 906.95K |
| Two Sigma Investments, LP | 1.72M | ▼ 318.99K |
| Kalehua Capital Management LLC | 1.65M | ▲ 382.02K |
| Marshall Wace, Llp | 1.12M | ▼ 680.05K |
| Lion Point Capital, LP | 820.00K | 0 |
| Toronto Dominion Bank | 750.00K | 0 |
| Ameriprise Financial Inc | 666.67K | 0 |
Held by 2 ETFs
Biggest fund positions in MIST by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Krick Anthony J | other | 0 |
| Jun 10, 26 | Giles Lisa M. | other | 77,000 |
| Jun 10, 26 | Fischer Seth H. Z. | other | 77,000 |
| Jun 10, 26 | Duty Stuart | other | 77,000 |
| Jun 10, 26 | Wills Robert James | other | 77,000 |
| Jun 10, 26 | TOMSICEK MICHAEL JOHN | other | 77,000 |
| Jun 10, 26 | Saik Andrew | other | 77,000 |
| Jun 10, 26 | PAPA JOSEPH C | other | 77,000 |
| Apr 16, 26 | Oliveto Joseph | sell | 36,500 |
| Mar 17, 26 | Sandoval David I. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MIST coverage
Recent articles, reports, and earnings notes.
No research on MIST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MIST report →Milestone Pharmaceuticals Analysts Cut Their Forecasts Following Q3 Results
benzinga.com · Nov 16
Milestone Pharmaceuticals Inc. (MIST) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Milestone Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 13
Milestone Pharmaceuticals (MIST) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 13
Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
globenewswire.com · Nov 13
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 3
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
globenewswire.com · Nov 3
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
globenewswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.